JP2005531627A - 新規混合医薬 - Google Patents

新規混合医薬 Download PDF

Info

Publication number
JP2005531627A
JP2005531627A JP2004517093A JP2004517093A JP2005531627A JP 2005531627 A JP2005531627 A JP 2005531627A JP 2004517093 A JP2004517093 A JP 2004517093A JP 2004517093 A JP2004517093 A JP 2004517093A JP 2005531627 A JP2005531627 A JP 2005531627A
Authority
JP
Japan
Prior art keywords
hypertension
pde5
inhibitor
methyl
angiotensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004517093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005531627A5 (zh
Inventor
ネイサン アブラハム フォックス，デイビッド
ヒューズ，バーナデット
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2005531627A publication Critical patent/JP2005531627A/ja
Publication of JP2005531627A5 publication Critical patent/JP2005531627A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004517093A 2002-06-26 2003-06-16 新規混合医薬 Withdrawn JP2005531627A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination
PCT/IB2003/002657 WO2004002461A2 (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists

Publications (2)

Publication Number Publication Date
JP2005531627A true JP2005531627A (ja) 2005-10-20
JP2005531627A5 JP2005531627A5 (zh) 2006-08-10

Family

ID=9939342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004517093A Withdrawn JP2005531627A (ja) 2002-06-26 2003-06-16 新規混合医薬

Country Status (20)

Country Link
EP (1) EP1524996A2 (zh)
JP (1) JP2005531627A (zh)
KR (1) KR20050013156A (zh)
CN (1) CN1662257A (zh)
AR (1) AR040337A1 (zh)
AU (1) AU2003242895A1 (zh)
BR (1) BR0312030A (zh)
CA (1) CA2491002A1 (zh)
GB (1) GB0214784D0 (zh)
GT (1) GT200300124A (zh)
MX (1) MXPA04012569A (zh)
NO (1) NO20050400L (zh)
PA (1) PA8575501A1 (zh)
PE (1) PE20040868A1 (zh)
PL (1) PL375079A1 (zh)
RU (1) RU2004136276A (zh)
TW (1) TW200404546A (zh)
UY (1) UY27863A1 (zh)
WO (1) WO2004002461A2 (zh)
ZA (1) ZA200409532B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
KR100722897B1 (ko) * 2002-07-26 2007-05-31 올림푸스 가부시키가이샤 화상 처리 시스템
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (pt) * 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
CA2611638C (en) 2005-06-10 2010-08-24 Dong A Pharm. Co. Ltd. Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative
WO2007010337A2 (de) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben
CA2625153A1 (en) * 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2377531A2 (en) * 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
HU230154B1 (hu) * 1997-11-12 2015-09-28 Bayer Intellectual Property Gmbh Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CZ20021151A3 (cs) * 1999-10-11 2003-03-12 Pfizer Inc. 5-(2-substituovaný-5-heterocyklylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ony jako inhibitory fosfodiesterasy
CA2419033A1 (en) * 2000-08-11 2002-02-21 Earl Michael Gibbs Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Also Published As

Publication number Publication date
BR0312030A (pt) 2005-03-22
PL375079A1 (en) 2005-11-14
EP1524996A2 (en) 2005-04-27
RU2004136276A (ru) 2005-09-10
PE20040868A1 (es) 2004-11-25
AU2003242895A1 (en) 2004-01-19
ZA200409532B (en) 2006-06-28
WO2004002461A3 (en) 2004-05-13
AR040337A1 (es) 2005-03-30
NO20050400L (no) 2005-03-29
PA8575501A1 (es) 2003-12-30
MXPA04012569A (es) 2005-04-19
TW200404546A (en) 2004-04-01
GT200300124A (es) 2004-03-17
CN1662257A (zh) 2005-08-31
WO2004002461A2 (en) 2004-01-08
CA2491002A1 (en) 2004-01-08
UY27863A1 (es) 2003-12-31
GB0214784D0 (en) 2002-08-07
KR20050013156A (ko) 2005-02-02

Similar Documents

Publication Publication Date Title
US20080318982A1 (en) Pharmaceutical Combination for the Treatment of Luts
US20040186046A1 (en) Treatment of type 1 diabetes with PDE5 inhibitors
US8329656B2 (en) Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders
HUE028008T2 (en) sGC stimulators or sGC activators alone and in combination with PDE5 inhibitors for the treatment of cystic fibrosis
JP2004506009A (ja) インスリン抵抗性症候群の治療
AU2001286832A1 (en) Method for treatment of migraine using PDE5 inhibitors
MXPA04007430A (es) Uso de inhibidores de pde5 en el tratamiento de cicatrices y fibrosis.
US20080261995A1 (en) Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor
KR20050004195A (ko) 신규 조합 제제
JP2005531627A (ja) 新規混合医薬
US20040132731A1 (en) Novel combination
JP2006520777A (ja) Ｐｄｅ５阻害剤を用いる１型糖尿病の治療
US20040077624A1 (en) Novel combination
EP1157705A2 (en) Use of a phosphodiesterase inhibitor in the manufacture of a medicament for blood pressure stabilization during hemodialysis
JP2003192614A (ja) 痛みを低減させるためのキット
JP2004520279A (ja) 早発射精の治療
US20050107405A1 (en) Pharmaceutical composition for alleviating pain or spasticity in a patient suffering from spinal cord injury
JP4904268B2 (ja) 低色素性障害を治療・予防するためのｐｄｅ５阻害剤、異性体、塩の使用

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060615

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20061114